Functional Imaging in Prediction of Response to Abemaciclib for Advanced Hormone Receptor-Positive, HER2-Negative Breast Cancer
Phase 2 Recruiting
60 enrolled
EvoPAR-BR01
Phase 3 Recruiting
500 enrolled
Testing the Addition of an Anti-Cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (5-Fluorouracil) for Metastatic, Refractory Colorectal Cancer
Phase 1 Recruiting
39 enrolled
Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 Recruiting
42 enrolled
A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer
Phase 1/2 Recruiting
316 enrolled
Abemaciclib in Combination With Bicalutamide for Androgen Receptor-positive, HER2-negative Metastatic Breast Cancer
Phase 1/2 Recruiting
42 enrolled
UPLIFT
Phase 1/2 Recruiting
30 enrolled
Testing the Safety and Efficacy of the Combination of Two Anti-cancer Drugs, ZEN003694 and Abemaciclib, for Adult and Pediatric Patients (12-17 Years) With Metastatic or Unresectable NUT Carcinoma, Breast Cancer and Other Solid Tumors
Phase 1 Recruiting
45 enrolled
Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue Sarcoma
Phase 1/2 Recruiting
74 enrolled
Safety and Tolerability of TNG456 Alone and in Combination With Abemaciclib in Patients With Solid Tumors With MTAP Loss
Phase 1/2 Recruiting
191 enrolled
EVOLVE-BDT
Phase 2 Recruiting
700 enrolled
A Study of Abemaciclib and Cabozantinib in People With Clear Cell Renal Cell Carcinoma (ccRCC)
Phase 1/2 Recruiting
43 enrolled
CYCAD-1
Phase 1/2 Recruiting
564 enrolled
Vismodegib, FAK Inhibitor GSK2256098, Capivasertib, and Abemaciclib in Treating Patients With Progressive Meningiomas
Phase 2 Recruiting
124 enrolled
ELAINEIII
Phase 3 Recruiting
500 enrolled
ELECTRA
Phase 1/2 Recruiting
73 enrolled
A Study to Evaluate Efficacy and Safety of Giredestrant Compared With Fulvestrant (Plus a CDK4/6 Inhibitor), in Participants With ER-Positive, HER2-Negative Advanced Breast Cancer Resistant to Adjuvant Endocrine Therapy (pionERA Breast Cancer)
Phase 3 Recruiting
1,050 enrolled
A Vaccine (STEMVAC) With Standard Endocrine-Based Therapy or Chemotherapy for the Treatment of Metastatic Hormone Receptor Positive, HER2 Negative Breast Cancer
Phase 2 Recruiting
40 enrolled
TAPUR
Phase 2 Recruiting
4,200 enrolled
EndoMAP
Phase 1/2 Recruiting
148 enrolled
Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas
Phase 1/2 Recruiting
55 enrolled
INX-315-01
Phase 1/2 Recruiting
150 enrolled
ABBICAR
Phase 2 Recruiting
53 enrolled
CAROLEEN
Recruiting
3,250 enrolled
CAMPFIRE
Phase 2 Recruiting
105 enrolled
Phase 1/2 Study to Evaluate EP0062 as Monotherapy and in Combination in Patients With Advanced or Metastatic AR+/HER-2-/ER+ Breast Cancer
Phase 1/2 Recruiting
95 enrolled
A Study of Tersolisib (LY4064809/STX-478) With Other Anti-Cancer Treatments in Participants With Advanced Breast Cancer With a Genetic Change (PIK3CA)
Phase 3 Recruiting
920 enrolled
A Study of Elacestrant Alone or in Combination With Abemaciclib in People With Endometrial Cancer
Phase 2 Recruiting
75 enrolled
Morpheus-panBC
Phase 1/2 Recruiting
792 enrolled
I-SPY
Phase 2 Recruiting
5,000 enrolled
Abemaciclib in Newly Diagnosed Meningioma Patients
Phase 2 Recruiting
72 enrolled
CAPItello-292
Phase 3 Recruiting
895 enrolled
A Study to Evaluate the Effect of GDC-4198 Alone and in Combination With Giredestrant Versus Abemaciclib and Giredestrant in Participants With Locally Advanced or Metastatic Estrogen Receptor-Positive (ER+), Human Epidermal Growth Factor Receptor-Negative (HER2-) Breast Cancer
Phase 1/2 Recruiting
285 enrolled
Anastrazole, Fulvestrant & Abemaciclib for HR+HER2- Metastatic Breast Cancer
Phase 2 Recruiting
20 enrolled
MiRaDoR
Phase 2 Recruiting
976 enrolled
FourLight-3
Phase 3 Recruiting
1,020 enrolled
A Study of Abemaciclib and Radiation Therapy in People With Metastatic Breast Cancer
Phase 1 Recruiting
28 enrolled
ALPINE: Maintenance Letrozole/Abemaciclib
Phase 2 Recruiting
32 enrolled
Stereotactic Radiation & Abemaciclib in the Management of HR+/HER2- Breast Cancer Brain Metastases
Phase 1/2 Recruiting
31 enrolled
Fulvestrant+Abemaciclib With Run-In of Fulvestrant in Er-Positive, Her2-Negative Metastatic Breast Cancer
Phase 2 Recruiting
28 enrolled
Abemaciclib in Patients With HIV-associated and HIV-negative Kaposi Sarcoma
Phase 1/2 Recruiting
86 enrolled
GERTRUDE
Phase 2 Recruiting
135 enrolled